← Back

PathMaker Neurosystems Receives Award from Non-Profit Consortium to Support Development of MyoAmplifier™ for the Non-Invasive Treatment of Pediatric Paralysis and Muscle Weakness

Boston, Mass., January 17, 2018PathMaker Neurosystems Inc. (“PathMaker”), a clinical-stage bioelectronic medicine company developing non-invasive systems for the treatment of patients with neuromotor disorders, announced today that it is the recipient of a funding award from the New England Pediatric Device Consortium (NEPDC).

The funding and in-kind services provided by the NEPDC will support development of PathMaker’s MyoAmplifier™ system, an advanced non-invasive platform that treats patients with paralysis and muscle weakness.

“We are honored to receive this award from NEPDC that will support application of MyoAmplifier to children with cerebral palsy,” said Nader Yaghoubi, M.D., Ph.D., President and Chief Executive Officer of PathMaker Neurosystems. “We are committed to bringing our first-in-class, non-invasive technology to children in desperate need of treatment options.”

Cerebral palsy (CP) is the most common of childhood disabilities, affecting 2-3 out of every 1,000 live births in the U.S. It is estimated that approximately 500,000 children under age 18 are living with CP in U.S., and 17 million people with CP worldwide. The essential aspect of CP is motor impairment, and between 25-30% of patients are unable to walk. As there are no effective interventions that can restore mobility for these patients, there is tremendous pediatric need for technologies that can improve motor function and restore mobility.

MyoAmplifier is an advanced non-invasive platform that integrates magnetic and electrical stimulation to treat patients with paralysis and weakness due to damaged neuromotor pathways. MyoAmplifier is based on our proprietary TripleStim™ technology, protected by issued U.S. and foreign patents, that provides simultaneous non-invasive stimulation at cortical, spinal and peripheral sites associated with targeted muscles to dramatically improve motor function.

MyoAmplifier is an investigational device and is limited by United States law to investigational use only.

About PathMaker Neurosystems Inc.

PathMaker Neurosystems is a clinical-stage bioelectronic medicine company developing breakthrough non-invasive systems for the treatment of patients with chronic neuromotor conditions. With offices in Boston (U.S.) and Paris (France), we are collaborating with world-class research institutions to rapidly bring to market disruptive products for treating spasticity, paralysis and muscle weakness. More than 48 million patients in the US, Europe and China suffer disabilities due to stroke, cerebral palsy, multiple sclerosis, spinal cord injury, traumatic brain injury, Parkinson’s disease and other neurological disorders. At PathMaker, we are opening up a new era of non-invasive neurotherapy for patients suffering from chronic neuromotor conditions.  For more information, please visit the company website at www.pmneuro.com.

About New England Pediatric Device Consortium (NEPDC)

NEPDC is a non-profit consortium that provides infrastructure, expert consultation to innovators, and execution of technology translation and commercialization of pediatric technologies. NEPDC offers commercialization resources for pediatric medical devices through a seed grant program made possible through funds from the FDA Office of Orphan Product Development. For further information, visit www.NEPDC.org.

Source: PathMaker Neurosystems Inc.

Media Contact:
Sharon Correia